Skip to main content

Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy

Abstract

Despite the numerous preclinical and clinical studies that have been conducted on metronomic chemotherapy in the past 10 years, few pharmacokinetic and pharmacogenetics data on this dosing regimen are available. Indeed, only the pharmacokinetics of metronomically administered drugs, such as irinotecan, UFT, and vinorelbine, have been described in patients, but no data are available on the most widely explored agents in such an approach like cyclophosphamide or capecitabine. Methodological issues and the neglected importance of the relationship between plasma concentrations of metronomically administered chemotherapeutic drugs (and their active metabolites) contributed to the absence of data on the commonly used 50 mg/day cyclophosphamide schedule. Moreover, few data are available on the pharmacogenetics of metronomic chemotherapy, and, although some objective responses have been obtained in various tumors, it remains largely unknown which genetic backgrounds could affect or predict the clinical response of patients. Trials integrating pharmacokinetic and pharmacogenetics research are necessary to better evaluate the clinical benefit of metronomic chemotherapy.

Keywords

  • Chemotherapeutic Drug
  • Area Under Curve
  • Metronomic Chemotherapy
  • Oral Vinorelbine
  • Solid Dispersion Formulation

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-662-43604-2_16
  • Chapter length: 18 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-662-43604-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   139.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)
Fig. 16.1
Fig. 16.2
Fig. 16.3

References

  1. Rowland M, Tozer TN (1995) Section II – therapeutic regimens. In: Clinical pharmacokinetics. Concepts and applications. Lippincott Williams & Wilkins, Media, Baltimore, pp 53–105

    Google Scholar 

  2. Gillis NK, Patel JN, Innocenti F (2014) Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther 95(3):269–280. doi:10.1038/clpt.2013.214

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  3. Roy P, Waxman DJ (2006) Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 20(2):176–186. doi:10.1016/j.tiv.2005.06.046

    CAS  PubMed  CrossRef  Google Scholar 

  4. Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 15(2):275–286. doi:10.1007/s10456-012-9260-6

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  5. Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M (2012) Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast 21(3):309–313. doi:10.1016/j.breast.2012.01.015

    PubMed  CrossRef  Google Scholar 

  6. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2):452–459. doi:10.1182/blood-2005-11-4570

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  7. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423–436. doi:10.1038/nrc1369

    CAS  PubMed  CrossRef  Google Scholar 

  8. Andre N, Padovani L, Verschuur A (2010) Metronomic chemotherapy: back to the future! Drug News Perspect 23(2):143–151. doi:10.1358/dnp.2010.23.2.1475913

    PubMed  CrossRef  Google Scholar 

  9. Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G (2008) A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 98(8):1312–1319. doi:10.1038/sj.bjc.6604311

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  10. Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E (2013) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13(1):263. doi:10.1186/1471-2407-13-263

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  11. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15(20):6454–6461. doi:10.1158/1078-0432.ccr-09-0970

    CAS  PubMed  CrossRef  Google Scholar 

  12. Turner DC, Tillmanns TD, Harstead KE, Throm SL, Stewart CF (2013) Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer. Anticancer Res 33(9):3823–3829

    CAS  PubMed  Google Scholar 

  13. Moes J, Koolen S, Huitema A, Schellens J, Beijnen J, Nuijen B (2013) Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur J Pharm Biopharm 83(1):87–94. doi:10.1016/j.ejpb.2012.09.016

    CAS  PubMed  CrossRef  Google Scholar 

  14. Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E (2006) Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer 42(14):2335–2342. doi:10.1016/j.ejca.2006.03.023

    CAS  PubMed  CrossRef  Google Scholar 

  15. Di Paolo A, Bocci G, Danesi R, Del Tacca M (2006) Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr Clin Pharmacol 1(3):311–323

    PubMed  CrossRef  Google Scholar 

  16. Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P (2001) Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 19(15):3456–3462

    CAS  PubMed  Google Scholar 

  17. Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW (1999) Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 17(6):1897–1905

    CAS  PubMed  Google Scholar 

  18. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G (2008) Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98(10):1619–1629. doi:10.1038/sj.bjc.6604352

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  19. Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62(2):259–271. doi:10.1136/gutjnl-2011-301585

    PubMed Central  PubMed  CrossRef  Google Scholar 

  20. Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS, Baruchel S (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656–5667. doi:10.1158/1078-0432.ccr-11-0078

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  21. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996–1006. doi:10.1158/1535-7163.mct-09-0960

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  22. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596–1603

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  23. Tillmanns TD, Stewart CF, MacEachern J, Schaiquevich P, Walker MS, Stepanski EJ (2008) Daily oral topotecan: utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. J Clin Oncol 26(15_suppl):2571

    Google Scholar 

  24. Kerklaan BM, Lolkema MPJK, Devriese LA, Voest EE, Nol-Boekel A, Mergui-Roelvink M, Mykulowycz K, Stoebenau JE, Fang L, Legenne P, Wissel PS, Smith DA, Giantonio BJ, Schellens JHM, Witteveen P (2013) Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors. J Clin Oncol 31(suppl):2536

    Google Scholar 

  25. Pasquier E, Andre N, Braguer D (2007) Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 7(6):566–581

    CAS  PubMed  CrossRef  Google Scholar 

  26. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15(8):2594–2601. doi:10.1158/1078-0432.ccr-08-2710

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  27. Bocci G, Di Paolo A, Danesi R (2013) The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis 16(3):481–492. doi:10.1007/s10456-013-9334-0

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  28. Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S (2013) A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother 25(1):49–55. doi:10.1179/1973947812y.0000000050

    CAS  PubMed  CrossRef  Google Scholar 

  29. Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70(4):603–609. doi:10.1007/s00280-012-1945-4

    CAS  PubMed  CrossRef  Google Scholar 

  30. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S (2010) Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer. Clin Breast Cancer 10(4):301–306. doi:10.3816/CBC.2010.n.039

    CAS  PubMed  CrossRef  Google Scholar 

  31. Gebbia V, Puozzo C (2005) Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 4(5):915–928. doi:10.1517/14740338.4.5.915

    CAS  PubMed  CrossRef  Google Scholar 

  32. Pappas P, Biziota I, Marselos M, Briasoulis E (2008) Evaluation of antiproliferative and molecular effects of vinorelbine and its active metabolite 4-Odeacetyl-vinorelbine on human endothelial cells in an in vitro simulation model of metronomic chemotherapy. Eur J Cancer 6:138–139

    CrossRef  Google Scholar 

  33. Byrne JD, Betancourt T, Brannon-Peppas L (2008) Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 60(15):1615–1626. doi:10.1016/j.addr.2008.08.005

    CAS  PubMed  CrossRef  Google Scholar 

  34. Luo LM, Huang Y, Zhao BX, Zhao X, Duan Y, Du R, Yu KF, Song P, Zhao Y, Zhang X, Zhang Q (2013) Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 34(4):1102–1114. doi:10.1016/j.biomaterials.2012.10.029

    CAS  PubMed  CrossRef  Google Scholar 

  35. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62(23):6938–6943

    CAS  PubMed  Google Scholar 

  36. Wang J, Lou P, Lesniewski R, Henkin J (2003) Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14(1):13–19

    PubMed  CrossRef  Google Scholar 

  37. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1):180–190

    CAS  PubMed  Google Scholar 

  38. Bennouna J, Saunders M, Douillard JY (2009) The role of UFT in metastatic colorectal cancer. Oncology 76(5):301–310. doi:10.1159/000209334

    CAS  PubMed  CrossRef  Google Scholar 

  39. Tanaka F, Wada H, Fukushima M (2010) UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg 58(1):3–13. doi:10.1007/s11748-009-0498-x

    PubMed  CrossRef  Google Scholar 

  40. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350(17):1713–1721. doi:10.1056/NEJMoa032792

    CAS  PubMed  CrossRef  Google Scholar 

  41. Penel N, Adenis A, Bocci G (2012) Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol 82(1):40–50. doi:10.1016/j.critrevonc.2011.04.009

    PubMed  CrossRef  Google Scholar 

  42. Chen C, Xu T, Lu Y, Chen J, Wu S (2013) The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol 20(2):223–230. doi:10.1111/j.1468-1331.2012.03778.x

    CAS  PubMed  CrossRef  Google Scholar 

  43. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40–48

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62(10):2731–2735

    CAS  PubMed  Google Scholar 

  45. Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay JY, Tresch-Bruneel E, Fournier C, Clisant S, Amela EY, Cassier PA, Molimard M, Penel N (2013) A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. Br J Cancer 109(10):2574–2578. doi:10.1038/bjc.2013.648

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  46. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321(1):265–275. doi:10.1124/jpet.106.118265

    CAS  PubMed  CrossRef  Google Scholar 

  47. Burt T, Dhillon S (2013) Pharmacogenomics in early-phase clinical development. Pharmacogenomics 14(9):1085–1097. doi:10.2217/pgs.13.81

    CAS  PubMed  CrossRef  Google Scholar 

  48. Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G (2013) VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer 109(4):957–964. doi:10.1038/bjc.2013.398

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  49. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14(22):7554–7563. doi:10.1158/1078-0432.ccr-08-0351

    CAS  PubMed Central  PubMed  CrossRef  Google Scholar 

  50. Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE, Libutti SK (2008) Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 14(1):270–280. doi:10.1158/1078-0432.ccr-07-1562

    CAS  PubMed  CrossRef  Google Scholar 

  51. Nagar S (2010) Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. Adv Exp Med Biol 678:124–132

    CAS  PubMed  CrossRef  Google Scholar 

Download references

Acknowledgments

The authors thank Giacomo Allegrini, Andrea Fontana, Anna Fioravanti, Paola Orlandi, and Teresa Di Desidero for their precious collaboration.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Guido Bocci MD, PhD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bocci, G., Francia, G. (2014). Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy. In: Bocci, G., Francia, G. (eds) Metronomic Chemotherapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43604-2_16

Download citation